Gannet BioChem welcomes Dr. Harry Rathore to Board
Company - People | Apr 22, 2025 | Ampersand Capital Partners
Gannet BioChem, a leader in the specialty chemical contract development and manufacturing organization sector, has announced Dr. Harry Rathore's addition to its Board of Directors. This follows its recent acquisition by Ampersand Capital Partners, a private equity firm specializing in healthcare and life sciences sectors. Dr. Rathore, with 35 years of experience in specialty chemicals and pharmaceuticals, also serves in advisory roles at Ascensus Specialties and VanDeMark, Inc. His appointment is expected to propel Gannet BioChem's strategic growth and innovation efforts, especially in the realm of polyethylene glycol (PEG) reagents, bioconjugation, and GMP manufacturing. CEO Nick Shackley regards Rathore's experience as vital to achieving the company's global therapeutic support mission.
Sectors
- Specialty Chemicals
- Healthcare and Life Sciences
Geography
- United States – Gannet BioChem operates a significant facility in Huntsville, Alabama, and Ampersand Capital Partners has an office in Boston, Massachusetts, anchoring their operations in the United States.
- Netherlands – Ampersand Capital Partners also has a presence with an office in Amsterdam, augmenting its international reach.
Industry
- Specialty Chemicals – Gannet BioChem operates as a specialty chemical Contract Development and Manufacturing Organization (CDMO), specializing in PEG reagents and bioconjugation for biopharmaceutical applications.
- Healthcare and Life Sciences – Ampersand Capital Partners, which recently acquired Gannet BioChem, focuses its investments in growth-oriented life sciences and healthcare sectors.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Gannet BioChem | Target Company | Company | A leading specialty CDMO with expertise in PEG reagents, bioconjugation, and GMP manufacturing. |
| Ampersand Capital Partners | Bidding Company | Company | A private equity firm focusing on healthcare and life sciences sectors, with $3 billion under management. |
| Dr. Harry Rathore | New Board Member | Person | An experienced leader in specialty chemicals and pharmaceuticals, appointed to Gannet BioChem's Board. |
| Nick Shackley | CEO of Gannet BioChem | Person | Chief Executive Officer at Gannet BioChem leading the company's growth and innovation strategy. |